Quest Diagnostics Incorporated DGX
Verdict: Strong sell. Fair value $158 against a price of $179 on 6 Jan 2026, 11% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Net Income has declined significantly from a peak of $2.00B in 2021 to $0.87B in 2024. This is....
Main risks
- Severe Profitability Decline: Net income and margins have collapsed from their 2021 peak ($2.0B Net Income) to current levels ($0.87B), indicating a sharp normalization post-COVID that has eroded profitability.
- High Leverage: The Debt-to-Equity ratio exceeds 1.0, and the estimated Net Debt-to-EBITDA ratio is high at ~3.75x, suggesting a potentially strained balance sheet, especially with declining earnings.
- Negative Return on Incremental Capital (ROIIC): A highly negative estimated 3-year ROIIC of -128% suggests that capital invested over the past three years has been value-destructive, coinciding with a steep drop in earnings from the pandemic peak.
- Intense competitive environment